Hematologic and cytogenetic response in phase II studies.
| (patients with confirmed diagnosis) . | Study 0110 Chronic phase, Interferon failure (n=454) . | Study 0109 Accelerated phase (n=181) . | Study 0102 Myeloid blast crisis (n=229) . |
|---|---|---|---|
| Hematologic response | 415 (91%) | 125 (69%) | 66 (29%) |
| Complete hematologic response | 415 (91%) | 61 (34%) | 16 (7%) |
| No evidence of leukemia | -22 (12%) | 7 (3%) | |
| Return to chronic phase | -42 (23%) | 43 (19%) | |
| Major cytogenetic response | 248 (55%) | 43 (24%) | 36 (16%) |
| Complete | 164 (36%) | 30 (17%) | 15 (7%) |
| Partial | 84 (19%) | 13 (7%) | 21 (9%) |
| (patients with confirmed diagnosis) . | Study 0110 Chronic phase, Interferon failure (n=454) . | Study 0109 Accelerated phase (n=181) . | Study 0102 Myeloid blast crisis (n=229) . |
|---|---|---|---|
| Hematologic response | 415 (91%) | 125 (69%) | 66 (29%) |
| Complete hematologic response | 415 (91%) | 61 (34%) | 16 (7%) |
| No evidence of leukemia | -22 (12%) | 7 (3%) | |
| Return to chronic phase | -42 (23%) | 43 (19%) | |
| Major cytogenetic response | 248 (55%) | 43 (24%) | 36 (16%) |
| Complete | 164 (36%) | 30 (17%) | 15 (7%) |
| Partial | 84 (19%) | 13 (7%) | 21 (9%) |